Publications

Probity Medical Research has compiled journals, articles and presentations for your personal review. Please use the search features below to find an article.

 

If you would like to request an article for personal review please complete the registration form. These publications are for personal use only and cannot be distributed. 

Register

 

Already granted access to an article?  

Login

 

If you cannot find the article you are looking for please contact Probity Medical Research. 

Journals, Articles and Presentations

Found 38 matches.
Page:
2
Refine your search to narrow the results.

What’s Your Diagnosis? Tender Honey-Colored Lesion With “Stuck-on” Crust

Consultant for Pediatricians 2013 Feb;12(2):83-85.

Journal
Consultant for Pediatricians
Condition
Impetigo
Author
Alexander K. C. Leung, Benjamin Barankin
Year
2013
Register & Request Access

Five Things to Know About Psoriasis

Canadian Medical Association Journal. 2013 Feb 19;185(3):E174. doi: 10.1503/cmaj.090631. Epub 2012 Sep 4.

Journal
Canadian Medical Association Journal
PubMed ID
22949562
Condition
Psoriasis
Author
Anatoli Freiman, Benjamin Barankin
Year
2013
Register & Request Access

Examining the Risk of Cardiovascular Disease in Patients with Psoriasis: A Critical Review

Journal of Cutaneous Medicine and Surgery 2013 Mar-Apr;17(2):89-105.

Journal
Journal of Cutaneous Medicine and Surgery (JCMS)
Condition
Psoriasis, Cardiovascular Disease, Atherosclerosis
Author
Kim Papp, Yves Poulin, Andrew Viera
Year
2013
Register & Request Access

Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Psoriasis: 16-Week Results of a Phase 3, Randomized, Controlled Trial (ESTEEM 1)

Presented at the 47th Congress of the German Society of Dermatology, May 1-4, 2013

Condition
Psoriasis
Author
Kristian Reich, Kim Papp, Craig Leonardi, Leon Kircik, Sergio Chimenti, ChiaChi Hu, Randall M. Stevens, Robert M. Day, Christopher E.M. Griffiths
Year
2013
Register & Request Access

Tofacitinib has no clinically significant effects in cells controlling chronic viral infection and reactivation

Presented at the International Investigative Dermatology (IID), Edinburgh, Scotland, United Kingdom, May 8-11, 2013

Condition
Psoriasis
Author
Valenzuela F, Papp K, Pariser D, Tyring S, Wolk R, Buonanno M, Valdez H
Year
2013
Register & Request Access

Understanding and Assessing Potential Serious Adverse Events: A Practical Approach to Understanding the Benefits and Harm of Psoriasis Treatments

Journal of Cutaneous Medicine and Surgery 2013 May-Jun;17(3):189-196.

Journal
Journal of Cutaneous Medicine and Surgery
PubMed ID
23673302
Condition
Psoriasis
Author
Kim Papp, Lyn Guenther, Neil Shear, Carin Binder, Jerry Tan, Charles Lynde, Wayne Gulliver, and Paul Stang
Year
2013
Register & Request Access

Dose-Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis

CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e44; doi:10.1038/psp.2013.22; advance online publication 22 May 2013

Journal
CPT: Pharmacometrics & Systems Pharmacology
Condition
Psoriasis
Author
H Tan, P Gupta, J Harness, R Wolk, S Chapel, A Menter, B Strober, RG Langley, S Krishnaswami and KA Papp
Year
2013
Register & Request Access

Tofacitinib ointment efficacy and biomarker improvement in psoriasis

Presented at International Investigative Dermatology (IID), Edinburgh, Scotland, United Kingdom, May 8-11, 2013

Condition
Psoriasis
Author
Ports W, Bissonnette R, Papp K, Khan S, Lan S, Mamolo C, Masek-Hammerman K, Stewart Z, Syed J, Zhan Y, Purohit V
Year
2013
Register & Request Access

Secukinumab effectively treats moderate-to-severe plaque psoriasis in a subset of patients able to maintain a response for as long as 24 weeks after cessation of therapy: Results of a dose finding study

Presented at Canadian Dermatology Association (CDA) 88th Annual Conference, Quebec City, Quebec, Canada, Jun 27-30, 2013

Condition
Psoriasis
Author
R.G. Langley, D.R. Baker, P. Rich, K. Papp, A. Guettner, C. Papavassilis
Year
2013
Register & Request Access

Safety of Ustekinumab From the Placebo-Controlled Periods of Psoriatic Arthritis and Psoriasis Clinical Developmental Programs

Presented at EULAR Annual European Congress of Rheumatology, Madrid, Spain, Jun 12-15, 2013

Condition
Psoriasis, Psoriatic Arthritis
Author
I. McInnes, K. Papp, L. Puig, K. Reich, C. Ritchlin, B. Strober, P. Rahman, A. Kavanaugh, A. Mendelsohn, M. Song, D. Chan, Y.K. Shen, S. Li, A.B. Gottlieb
Year
2013
Register & Request Access
Page:
2

Copyright 2014 Probity Medical Research Inc. All Rights Reserved.

Login